Wyeth Says Fracture Data Review Will Delay Viviant Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is expected to issue an “approvable” letter April 23 for the osteoporosis therapy requesting three-year fracture data, pushing action date to year-end.